Literature DB >> 31069724

In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections.

Julian Marcon1, Sören Schubert2, Christian G Stief1, Giuseppe Magistro3.   

Abstract

PURPOSE: To analyse the therapeutic efficacy of various phytotherapeutics and their antimicrobial compounds with regard to strain specificity and dose dependence.
METHODS: A representative strain collection of 40 uropathogenic bacteria isolated from complicated and uncomplicated urinary tract infection was subjected to various virulence assays (bacterial growth, mannose-sensitive agglutination, and motility) to determine the therapeutic impact of various compounds with antimicrobial activity. We tested proanthocyanidins (PAC), D-mannose, rosemary extract (Canephron®), and isothiocyanates (Angocin®).
RESULTS: D-mannose efficiently blocked the adhesive properties of all type 1 fimbriae-positive isolates in low concentration (0.2%), but showed no bacteriostatic effect. PAC also actively blocked agglutination, but the concentration varied considerably among isolates. Escherichia coli required the highest concentration (10%), while Enterobacter cloacae responded to low concentrations (0.1%). Allyl isothiocyanates not only impaired agglutination in all tested isolates, but also had a dramatic impact on flagella-mediated motility in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (p < 0.001). The administration of rosemary extracts revealed a strong bacteriostatic effect in growth assays. All tested strains were strongly inhibited by the addition of 10 μg/ml or 1 μg/ml of purified rosemary extractions with the exception of Serratia marcescens. Morganella morganii responded only to 10 μg/ml.
CONCLUSION: Phytotherapeutics and small-molecular compounds like mannosides have the potential to become an integral part in a multi-modal treatment concept for the treatment and prevention of urinary tract infections. Their efficiency can be optimised when strain specificities and therapeutic concentrations are taken into account.

Entities:  

Keywords:  Phytotherapeutics; Prevention; Therapy; Urinary tract infections; Uropathogenic Escherichia coli (UPEC)

Mesh:

Substances:

Year:  2019        PMID: 31069724     DOI: 10.1007/s15010-019-01315-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  34 in total

Review 1.  Urinary tract infections: disease panorama and challenges.

Authors:  W E Stamm; S R Norrby
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

Review 2.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

3.  Urologic diseases in America Project: analytical methods and principal findings.

Authors:  Mark S Litwin; Christopher S Saigal; Elizabeth M Yano; Chantal Avila; Sandy A Geschwind; Jan M Hanley; Geoffrey F Joyce; Rodger Madison; Jennifer Pace; Suzanne M Polich; Mingming Wang
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

4.  Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract.

Authors:  M Chelsea Lane; Christopher J Alteri; Sara N Smith; Harry L T Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-09       Impact factor: 11.205

5.  Vaccines for the prevention of recurrent urinary tract infections: a systematic review.

Authors:  Nikoo Aziminia; Marios Hadjipavlou; Yiannis Philippou; Shivkumar S Pandian; Sachin Malde; Mohamed Y Hammadeh
Journal:  BJU Int       Date:  2018-12-19       Impact factor: 5.588

6.  Biological activities of Rosmarinus officinalis L. (rosemary) extract as analyzed in microorganisms and cells.

Authors:  Jonatas Rafael de Oliveira; Daiane de Jesus; Leandro Wagner Figueira; Felipe Eduardo de Oliveira; Cristina Pacheco Soares; Samira Estves Afonso Camargo; Antonio Olavo Cardoso Jorge; Luciane Dias de Oliveira
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-17

Review 7.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

8.  Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.

Authors:  Angela Huttner; Christoph Hatz; Germie van den Dobbelsteen; Darren Abbanat; Alena Hornacek; Rahel Frölich; Anita M Dreyer; Patricia Martin; Todd Davies; Kellen Fae; Ingrid van den Nieuwenhof; Stefan Thoelen; Serge de Vallière; Anette Kuhn; Enos Bernasconi; Volker Viereck; Tilemachos Kavvadias; Kerstin Kling; Gloria Ryu; Tanja Hülder; Sabine Gröger; David Scheiner; Cristina Alaimo; Stephan Harbarth; Jan Poolman; Veronica Gambillara Fonck
Journal:  Lancet Infect Dis       Date:  2017-02-24       Impact factor: 25.071

9.  Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study.

Authors:  Zafer Tandogdu; Mete Cek; Florian Wagenlehner; Kurt Naber; Peter Tenke; Edgar van Ostrum; Truls Bjerklund Johansen
Journal:  World J Urol       Date:  2013-08-24       Impact factor: 4.226

10.  The high-pathogenicity island (HPI) promotes flagellum-mediated motility in extraintestinal pathogenic Escherichia coli.

Authors:  Giuseppe Magistro; Christiane Magistro; Christian G Stief; Sören Schubert
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

View more
  1 in total

Review 1.  Antibacterial Activity of Medicinal Plants against Uropathogenic Escherichia coli.

Authors:  Razan Salman Marouf; Joseph Arsene M Mbarga; Andrey V Ermolaev; Irina V Podoprigora; Irina P Smirnova; Natalia V Yashina; Anna V Zhigunova; Aliya V Martynenkova
Journal:  J Pharm Bioallied Sci       Date:  2022-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.